

May 30, 2026

To
The Manager – Listing Department
National Stock Exchange India Limited
Exchange Plaza, Plot No. C/1, Block-G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Symbol: VILINBIO

Sub: Outcome of Board Meeting held on May 30, 2026

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, the Board of Directors of the Company in its Meeting held today has considered and approved the following:

1. Audited Financial Results for the Half-year and Year ended March 31, 2026
2. Statement of Assets and Liabilities for the Year ended March 31, 2026
3. Cash Flow Statement for the Year ended as at March 31, 2026
4. Auditors Report for the Financial Results for the Year ended March 31, 2026
5. Statement of Deviation for the period ended March 31, 2026
6. Declaration pursuant to Regulation 33(3)(d) for the Auditors Report with Unmodified Opinion

In furtherance to the Intimation filed by the Company dated March 27, 2026 the Trading Window for trading in the Securities of the Company, which was closed from April 1, 2026 to till 48 hours after the declaration of Audited Standalone Financial Results, shall be opened after the expiry of forty-eight hours after declaration of the said Results.

The Meeting of the Board of Directors commenced at 12:00 P.M. and concluded at 1:50 P.M.

This is for your information and record.

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260

**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE HALF-YEAR AND YEAR ENDED
MARCH 31, 2026**

(Rs. in Lakhs)

	Particulars	Half - Year Ended			Year Ended	
		31-Mar	30-Sep	31-Mar	31-Mar	31-Mar
		2026	2025	2025	2026	2025
		Audited	Unaudited	Audited	Audited	Audited
I	Income					
(a)	Revenue from Operations	3,259.90	966.40	1,031.67	4,226.30	1,480.99
(b)	Other Income	0.12	-	25.23	0.12	46.85
	Total Revenue	3,260.02	966.40	1,056.90	4,226.41	1,527.84
II	Expenses					
(a)	Cost of Materials Consumed	2,866.01	896.73	969.44	3,762.74	1,347.23
(b)	Purchase of Stock-in-Trade	-	-	-	-	-
(c)	Changes in Inventories of Stock-in-Trade, Work-In-Progress and Finished Goods	-	-	-	-	-
(d)	Employee Benefit Expenses	55.80	18.29	16.48	74.09	29.50
(e)	Finance Cost	0.11	6.77	43.58	6.88	84.51
(f)	Depreciation and Amortisation Expenses	21.03	7.45	2.99	28.48	10.44
(g)	Other Expenses	52.35	17.78	9.20	70.14	25.57
	Total Expenses	2,995.31	947.02	1,041.70	3,942.33	1,497.26
III	Profit / (Loss) Before Exceptional Items and Tax	264.71	19.38	15.20	284.09	30.58
	Exceptional Items	-	-	-	-	-
	Profit / (Loss) Before Tax	264.71	19.38	15.20	284.09	30.58
IV	Tax Expense:					
	(1) Current Tax	83.20	4.63	4.10	87.83	6.95
	(2) Deferred Tax	3.80	(0.42)	1.19	3.38	1.28
	Profit / (Loss) for the Period from Continuing Operations	177.71	15.17	9.91	192.88	22.35
	Profit / (Loss) from Discontinued Operations	-	-	-	-	-
	Tax Expense of Discontinued Operations	-	-	-	-	-
	Profit / (Loss) from Discontinued Operations (After Tax)	-	-	-	-	-
V	Profit / (Loss) for the Period	177.71	15.17	9.91	192.88	22.35
	Other Comprehensive Income					
	A (i) Items that will not be reclassified to Profit	-	-	-	-	-

Registered Office: 8-2-269/S/43, Plot No. 43, 2nd Floor, Sagar Co-op Housing Society Limited, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

GST: 36AACCV1433D1ZR

E-mail: cs@vilinbiomed.co.in

Website: www.vilinbio.com

	or Loss					
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-
	B (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-
	Total Comprehensive Income for the period (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	-	-	-	-	-
VI	EPS - Basic and Diluted (In ₹)	1.26	0.11	0.07	1.37	0.16

Notes to Accounts:

1. The Financial Results of the Company for the Year ended March 31, 2026 have been audited by the Statutory Auditors of the Company. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on May 30, 2026.
2. The Financial results are prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognised Accounting Practices and Policies as applicable.
3. The Financial Statements includes the result for the Half-year ended March 31, 2026 being the balancing figure between Audited Figures in respect of full Financial Year ended March 31, 2026 and the figures for the six months period ended September 30, 2025 which was subjected to Limited Review by the Statutory Auditors
4. The Company's business activity primarily falls within a single business segment i.e., manufacturing of pharmaceutical products
5. Previous period figures have been reclassified and regrouped wherever considered necessary to confirm to the current period figures.
6. During the Current Financial Year, the Company allotted 13,00,000 Equity Shares on Preferential Basis issued at Face Value of Rs.10/- and at Premium of Rs.16/- Per Share.

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
 Managing Director
 DIN: 02874260

STATEMENT OF ASSETS AND LIABILITIES AS AT MARCH 31, 2026

(Rs. in Lakhs)

	Particulars	As at 31-Mar-2026	As at 31-Mar-2025
		Audited	Audited
I	EQUITY AND LIABILITIES		
(A)	Shareholders Funds		
(a)	(a) Share Capital	1,525.00	1,395.00
(b)	(b) Reserves and Surplus	1,312.24	911.35
(c)	(c) Money received against Share Warrants	-	-
		2,837.24	2,306.25
(B)	Non-Current Liabilities		
(a)	Long Term Borrowings	-	-
(b)	Other Long Term Liabilities	12.81	9.44
(c)	Deferred Tax Liabilities (Net)	-	-
(d)	Other Non-Current Liabilities	-	-
		12.81	9.44
(C)	Current Liabilities		
(a)	Short Term Borrowings	20.59	257.33
(b)	Trade Payables		
	(i) Total Outstanding due to MSME Unit	-	-
	(ii) Total Outstanding dues other than MSME	335.49	143.88
(c)	Other Current Liabilities	206.35	2.38
(d)	Short Term Provisions	81.73	58.70
		644.17	462.29
	Total Equity and Liabilities	3,494.22	2,778.08
II	ASSETS		
(A)	Non-Current Assets		
(a)	Property, Plant and Equipment and Intangible Assets		
	(i) Property, Plant and Equipment	286.51	128.46
	(ii) Capital work-in-progress	-	156.84
	(iii) Intangible Assets	-	-
(b)	Non - Current Investments	-	-
(c)	Deferred Tax Assets (Net)	-	-
(d)	Long Term Loans and Advances	-	-
(e)	Other Non-Current Assets	469.41	504.71
		755.92	790.01
(B)	Current Assets		
(a)	Inventories	721.53	441.18

(b)	Trade Receivables		1,595.62	855.51
(c)	Cash and Cash Equivalents		146.99	5.61
(d)	Short Term Loans and Advances		43.29	574.58
(e)	Other Current Assets		230.87	111.19
			2,738.30	1,988.07
	Total Assets		3,494.22	2,778.08

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260



CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2026		
(Rs. in Lakhs)		
Particulars	As at 31-Mar-2026	As at 31-Mar-2025
	Audited	Audited
Cash Flow from Operating Activities		
Net Profit Before Tax and Extra-ordinary Items	284.09	30.58
Adjustment For		
Depreciation	28.48	10.44
Foreign Exchange		
Gain or Loss on Sale of Fixed Assets		
Gain or Loss on Sale of Investment		
Finance Cost	-	84.51
Dividend Income		
Other adjustment of Non-Cash Item		
Other adjustment to reconcile Profit		
	28.48	94.95
Adjustment for Working Capital Change		
Adjustment for Increase/Decrease in Inventories	(280.35)	5.57
Adjustment for Increase/Decrease in Trade Receivables	(740.11)	(62.16)
Adjustment for Increase/Decrease in Other Current Assets	(84.39)	64.43
Adjustment for Increase/Decrease in Long term Loans and Advances	-	-
Adjustment for Increase/Decrease in Short Term Loans and Advances	531.29	-
Adjustment for Increase/Decrease in Trade Payables	191.61	(56.49)
Adjustment for Increase/Decrease in Other Current Liabilities	203.97	(1.44)
Adjustment for Provisions	23.03	(0.18)
Total Adjustment for Working Capital (B)	(154.94)	(50.28)
Total Adjustment to reconcile Profit (A+B)	(126.46)	44.67
Net Cash Flow From (used in) Operations	157.63	75.26
Dividend Received		
Interest Received	-	(46.56)
Interest Paid		
Income Tax Paid / Refund	(87.83)	(6.95)
Net Cash Flow From (used in) Operations before Extra-ordinary Items	69.80	21.75
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from Operating Activities	69.80	21.75
Cash Flows from Investing Activities		

Proceeds from Fixed Assets		
Proceeds from Investment or Equity Instruments		
Purchase of Fixed Assets	(29.68)	157.47
Purchase of Investments or Equity Instruments		
Interest Received	-	46.56
Dividend Received		
Cash Receipt from Sale of Interest in Joint Venture		
Cash Payment to acquire Interest in Joint Venture		
Cash Flow from loosing Control of Subsidiaries		
Cash Payment for acquiring Control of Subsidiaries		
Proceeds from Government Grant		
Other Inflow / Outflow of Cash		
Net Cash Flow From (used in) in Investing Activities before Extra-ordinary Items	(29.68)	(110.91)
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Item		
Net Cash Flow From (used in) in Investing Activities	(29.68)	(110.91)
Cash Flows from Financial Activities		
Proceeds from Issue of Shares	130.00	-
Proceeds from Issuing shares for security premium	208.00	-
Proceeds from Issue of Debenture / Bonds / Notes		
Redemption of Preference Shares		
Redemption of Debentures		
Proceeds from other Equity Instruments		
Proceeds from Borrowing		
Repayment of Borrowing	(236.74)	425.66
Dividend Paid		
Interest Paid		84.51
Income Tax Paid / Refund		
Net Cash Flow from (Used in) in Financial Activities before Extra-ordinary Items	101.26	(510.17)
Proceeds from Extra-ordinary Items		
Payment for Extra-ordinary Items		
Net Cash Flow from (Used in) in Financial Activities	101.26	(510.17)

Registered Office: 8-2-269/S/43, Plot No. 43, 2nd Floor, Sagar Co-op Housing Society Limited, Road No. 2, Banjara Hills
 Khairatabad, Hyderabad – 500034

Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667

Tel No: 040- 79618843

CIN: L24230TG2005PLC046689

GST: 36AACCV1433D1ZR

E-mail: cs@vilinbiomed.co.in

Website: www.vilinbio.com

Net Increase (Decrease) in Cash and Cash Equivalents before effect of Exchange Rate changes	141.38	(599.33)
Effect of Exchange Rate change on Cash and Cash Equivalents		
Net Increase (Decrease) in Cash and Cash Equivalents	141.38	(599.33)
Cash and Cash Equivalents at beginning of period	5.61	604.94
Cash and Cash Equivalents at end of period	146.99	5.61

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
 Managing Director
 DIN: 02874260



**Auditor's Report on Standalone Financial Results pursuant to Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

To
The Board of Directors
Vilin Bio Med Limited
Hyderabad

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying Standalone Financial Results of **Vilin Bio Med Limited** ("the Company") for the year ended March 31, 2026 and the Year-to-date Results for the period from April 1, 2025 to March 31, 2026 attached herewith being submitted by the Company, pursuant to requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations") including relevant Circulars issued by the Securities and Exchange Board of India (SEBI) from time to time.

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Statements:

- i. Are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. Gives a true and fair view in conformity with the Recognition and Measurement Principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other Accounting Principles generally accepted in India, of the Net Profit, Other Comprehensive Income and Other Financial Information of the Company for the Year ended March 31, 2026 as well as for the Year-to-Date Results for the period from April 1, 2025 to March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Results* section of the Report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India, together with the ethical requirements that are relevant to our audit of the Financial Results, under the provisions of the Act and Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the Audit Evidence obtained by us is sufficient and appropriate to provide a basis for our Opinion.



Management's Responsibilities for the Standalone Financial Results

This statement includes the Yearly Financial Results as well as Year-to-Date Standalone Financial Results have been prepared on basis of the Standalone Annual Financial Statements. The Company's Board of Directors are responsible for the preparation of these Financial Results that give a true and fair view of the Net Profit and Other Comprehensive Income and Other Financial Information in accordance with the Recognition and Measurement Principles, as laid down in Indian Accounting Standards, as prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other Accounting Principles generally accepted in India and in compliance with the Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate Accounting Records in accordance with the provisions of the Act for safeguarding of the Assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate Accounting Policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate Internal Financial Controls that were operating effectively for ensuring the accuracy and completeness of the Accounting Records, relevant to the preparation and presentation of the Financial Results, that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a 'Going Concern', disclosing, as applicable, matters related to going concern and using the 'Going Concern' basis of accounting, unless the Board of Directors either intends to liquidate the Company or to cease the operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Financial Reporting Process of the Company.

Auditor's Responsibilities

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole, are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an Audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As part of an Audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the Audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform Audit Procedures responsive to those risks, and obtain Audit Evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of Internal Controls.
- Evaluate the appropriateness of the Accounting Policies used and the reasonableness of Accounting Estimates made by the Board of Directors.



- Evaluate the appropriateness and reasonableness of the disclosures made by the Board of Directors in terms of requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the 'Going Concern' basis of accounting and, based on the Audit Evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a Going Concern. If we conclude that material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the Audit Evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Company to cease to continue as a Going Concern.
- Evaluate the overall presentation, structure, and content of the Standalone Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the Internal Controls that we identify during our Audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the Results for Year ended March 31, 2026 being the balancing figure between the Audited Figures in respect of the full Financial Year ended March 31, 2026 and the published Year-to-date figures up to half-year of the Current Financial Year, which were subjected to Limited Review by us, as required under the Listing Regulations.

For PPKG & Co
Chartered Accountants
FRN: 009655S

Girdhari Lal Toshniwal

Girdhari Lal Toshniwal
(Partner)

M. No. 205140
UDIN: 26205140FLM5K8719



Date: 30.05.2026
Place: Hyderabad

May 30, 2026

To
The Manager – Listing Department
National Stock Exchange India Limited
Exchange Plaza, Plot No. C/1, Block-G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Symbol: VILINBIO


Sub: Statement of Deviation or Variation in Utilisation of Funds Raised

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Statement of Deviation or variation in utilisation of Funds raised through Preferential Issue of Equity Shares. We hereby confirm that there is no deviation or variation in the use of proceeds raised from the Preferential Issue of Equity Shares.

This is for your information and record.

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260



Name of Listed Entity	Vilin Bio Med Limited
Mode of Fund Raising	Preferential Issue
Date of Raising Funds	March 4, 2026
Amount Raised	Rs.338.00 Lakhs
Report filed for half-year ended	March 31, 2026
Monitoring Agency	NA
Monitoring Agency Name	NA
Is there a Deviation / Variation in use of Funds raised ?	No
Whether any approval is required to vary the Objects of the Issue stated in the Prospectus / Offer Document?	No
If yes, details of the approval so required?	NA
Date of Approval	NA
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	Nil
Comments of the Auditors, if any	Nil
Objects for which Funds have been raised and wherethere has been a deviation, in the following table	No Deviation



5-8-352, 701, 7th Floor, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad - 500 001.

Branch Office : VIJAYAWADA

Ph : +91-40-23205049, 6613 2176, 3516 5760 | E-mail : giri@ppkg.com | www.batgach.com

Associate Office at : • AHMEDABAD • BANGALORE • CHENNAI • DELHI • GUWAHATI • JAIPUR • JODHPUR • INDORE • KOLKATA
• MUMBAI • PATNA • TRIVANDRUM • SILCHAR (ASSAM)

Original Object	Modified Object	Original Allocation (Rs. in Lakhs)	Modified Allocation	Funds Utilised (Rs. in Lakhs)	Balance Amount (Rs. in Lakhs)	Amount of Deviation / Variation for the applicable Object
Working Capital	NA	327.00	NA	187.05	139.95	NA
Issue Expenses	NA	11.00	NA	10.88	0.12	NA
Total		338.00		197.93	140.07	

The balance amount is maintained with Scheduled Commercial Bank.

Deviation could mean:

- Deviation in the Objects or purposes for which the Funds have been raised
- Deviation in the amount of Funds actually utilized as against what was originally disclosed.
- Change in terms of Contract referred to the Fund-raising document i.e., Prospectus / Letter of Offer, etc.

Date: 30/05/2026

Place: Hyderabad

**For PPKG & Co
Chartered Accountants
FRN: 009655S**

**CA Swetha Toshniwal
Partner
M. No. 231499**

UDIN: 26281499567JKTX6153

May 30, 2026

To
The Manager – Listing Department
National Stock Exchange India Limited
Exchange Plaza, Plot No. C/1, Block-G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Symbol: VILINBIO

Sub: Declaration in respect of Unmodified Opinion on the Audited Standalone Financial Results for the Financial Year ended March 31, 2026

Ref: Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, as amended, it is hereby declared and confirmed that the Statutory Auditors of the Company, PPKG & Co, Chartered Accountants (FRN: 009655S) have issued the Audit Report with an Unmodified Opinion in respect of the Standalone Financial Results for the Financial Year ended March 31, 2026.

The above is for your information and record.

For Vilin Bio Med Limited

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260